Aralez Pharma (ARLZ) will resume trading at 10:00am ET
- Stocks face worst month since September, yen swings after BoJ
- Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Oil prices on track to snap two-week losing streak
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Guggenheim Reiterates Buy on Aralez Pharma (ARLZ) Following Yosprala Approval
September 15, 2016 4:00 PM EDTGuggenheim reiterated a Buy rating and $12.00 price target on Aralez Pharmaceuticals (NASDAQ: ARLZ) following the approval of Yosprala and the recent acquisition of Zontivity. Yosprala will complement ARLZ's Fibricor, which is another CV drug that ARLZ already markets, and Zontivity, which ARLZ recently acquired.... More
Aralez Pharma (ARLZ) Halted on LUDP
September 15, 2016 10:00 AM EDTAralez Pharma (NASDAQ: ARLZ) Halted on LUDP
... MoreAralez Pharma (ARLZ) Announces FDA Approval for YOSPRALA
September 15, 2016 9:35 AM EDTAralez Pharmaceuticals Inc. (NASDAQ: ARLZ) announced today that the U.S. Food and Drug Administration (FDA) has approved once-daily YOSPRALA, the only prescription fixed-dose combination of aspirin, an anti-platelet agent, and omeprazole, a proton pump inhibitor (PPI) in the U.S. YOSPRALA is indicated for patients who require aspirin for secondary prevention of cardiovascular (CV) and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. The Company is expanding its U.S. sales force by 85... More
Aralez Pharma (ARLZ) trading halted with news pending
September 15, 2016 7:01 AM EDTAralez Pharma (NASDAQ: ARLZ) trading halted with news pending.
... MoreAralez Pharma (ARLZ) Slammed, Halted Ahead of PDUFA Date
September 14, 2016 11:40 AM EDTAralez Pharma (NASDAQ: ARLZ) has resumed trading and is down 14%. Today is the company's PDUFA date for YOSPRALA.
... MoreAralez Pharma (ARLZ) Halted on LUDP
September 14, 2016 11:36 AM EDTAralez Pharma (NASDAQ: ARLZ) Halted on LUDP
... More